Genovis AB (publ.) (STO:GENO)
Sweden · Delayed Price · Currency is SEK 19.90
+0.50 (2.58%)
May 4, 2026, 5:29 PM CET
Genovis AB (publ.) Revenue
Genovis AB (publ.) had revenue of 36.92M SEK in the quarter ending March 31, 2026, with 13.21% growth. This brings the company's revenue in the last twelve months to 133.84M, up 8.05% year-over-year. In the year 2025, Genovis AB (publ.) had annual revenue of 129.93M, down -1.06%.
Revenue (ttm)
133.84M
Revenue Growth
+8.05%
P/S Ratio
9.58
Revenue / Employee
3.72M
Employees
36
Market Cap
1.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 129.93M | -1.39M | -1.06% |
| Dec 31, 2024 | 131.32M | -27.75M | -17.44% |
| Dec 31, 2023 | 159.07M | 55.51M | 53.60% |
| Dec 31, 2022 | 103.56M | 9.89M | 10.55% |
| Dec 31, 2021 | 93.68M | 32.65M | 53.49% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Saniona AB | 434.40M |
| Cantargia AB | 316.70M |
| BioInvent International AB | 217.86M |
| Hansa Biopharma AB | 190.49M |
| Egetis Therapeutics AB | 63.10M |
| Medivir AB | 8.51M |
| Flerie AB | 1.80M |
| Xspray Pharma AB | 1.10M |
Genovis AB (publ.) News
- 1 year ago - Genovis AB (OSTO:GENO) Q3 2024 Earnings Report Preview: What to Expect - GuruFocus